Figure 3  .

Marked suppression of established AA by early, repeated OX34 mAb injections plus a dexamethasone pulse over two days. Sixteen rats were injected with FCA and 12 rats developed AA by day 12 (AS ⩾ 2). These were randomised into three groups, four animals each, and received blindly either dexamethasone plus OX34 starting on day 12 (n = 4), dexamethasone plus control mAb (AICD 58.6) starting on day 12 (n = 4), or dexamethasone plus OX34 starting on day 18 (n = 4). PBS was given on those days when no mAb was injected (for example, day 12 to 14 for dexamethasone plus OX34). Dexamethasone diluted in PBS was given at a concentration of 1 mg/kg body weight on two consecutive days, mAbs were injected for three consecutive days starting with 2 mg followed by 1 mg per day. Arthritis score (A) and hindpaw thickness (B) were measured by a blinded investigator at indicated time points. Symbols and labelling as in figure 2.